Tags

Type your tag names separated by a space and hit enter

Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens.
J Anal Toxicol. 2006 Jun; 30(5):319-22.JA

Abstract

The Roche Abuscreen Onlinetrade mark Amphetamine immunoassay (IA), modified to include sodium periodate, and the Microgenics DRI Ecstasy IA were used to determine the prevalence of amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in urine specimens from applicants seeking to join the United States Armed Forces. Over a 4-month period, a total of 85,658 specimens were IA screened using the Department of Defense 500 ng/mL administrative cutoff level for AMP and MDMA. All presumptively positive specimens were confirmed using a solid-phase extraction procedure coupled with simultaneous analysis of AMP, MAMP, MDA, MDMA, and MDEA by fast gas chromatography-mass spectrometry using the same cutoff levels as the IA. The Roche Online Amphetamine IA identified 216 specimens as presumptively positive; of these, 70 specimens confirmed positive for AMP and 87 specimens confirmed positive for AMP and/or MAMP, resulting in a confirmation rate of 73%. The Microgenics DRI Ecstasy IA identified eight specimens as presumptively positive; of these, five specimens confirmed positive for MDMA and/or MDA, resulting in a confirmation rate of 63%. The total use prevalence for AMP, MAMP, MDA, MDMA, and/or MDEA in military entrance processing stations specimens over the testing period was determined to be 0.19%.

Authors+Show Affiliations

Navy Drug Screening Laboratory, 320B B Street, Great Lakes, Illinois 60088-2815, USA. klklette@nhgl.med.navy.milNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16839469

Citation

Klette, Kevin L., et al. "Prevalence of Use Study for Amphetamine (AMP), Methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in Military Entrance Processing Stations (MEPS) Specimens." Journal of Analytical Toxicology, vol. 30, no. 5, 2006, pp. 319-22.
Klette KL, Kettle AR, Jamerson MH. Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens. J Anal Toxicol. 2006;30(5):319-22.
Klette, K. L., Kettle, A. R., & Jamerson, M. H. (2006). Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens. Journal of Analytical Toxicology, 30(5), 319-22.
Klette KL, Kettle AR, Jamerson MH. Prevalence of Use Study for Amphetamine (AMP), Methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in Military Entrance Processing Stations (MEPS) Specimens. J Anal Toxicol. 2006;30(5):319-22. PubMed PMID: 16839469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens. AU - Klette,Kevin L, AU - Kettle,Aaron R, AU - Jamerson,Matthew H, PY - 2006/7/15/pubmed PY - 2006/12/9/medline PY - 2006/7/15/entrez SP - 319 EP - 22 JF - Journal of analytical toxicology JO - J Anal Toxicol VL - 30 IS - 5 N2 - The Roche Abuscreen Onlinetrade mark Amphetamine immunoassay (IA), modified to include sodium periodate, and the Microgenics DRI Ecstasy IA were used to determine the prevalence of amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in urine specimens from applicants seeking to join the United States Armed Forces. Over a 4-month period, a total of 85,658 specimens were IA screened using the Department of Defense 500 ng/mL administrative cutoff level for AMP and MDMA. All presumptively positive specimens were confirmed using a solid-phase extraction procedure coupled with simultaneous analysis of AMP, MAMP, MDA, MDMA, and MDEA by fast gas chromatography-mass spectrometry using the same cutoff levels as the IA. The Roche Online Amphetamine IA identified 216 specimens as presumptively positive; of these, 70 specimens confirmed positive for AMP and 87 specimens confirmed positive for AMP and/or MAMP, resulting in a confirmation rate of 73%. The Microgenics DRI Ecstasy IA identified eight specimens as presumptively positive; of these, five specimens confirmed positive for MDMA and/or MDA, resulting in a confirmation rate of 63%. The total use prevalence for AMP, MAMP, MDA, MDMA, and/or MDEA in military entrance processing stations specimens over the testing period was determined to be 0.19%. SN - 0146-4760 UR - https://www.unboundmedicine.com/medline/citation/16839469/Prevalence_of_use_study_for_amphetamine__AMP__methamphetamine__MAMP__34_methylenedioxy_amphetamine__MDA__34_methylenedioxy_methamphetamine__MDMA__and_34_methylenedioxy_ethylamphetamine__MDEA__in_military_entrance_processing_stations__MEPS__specimens_ L2 - https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/30.5.319 DB - PRIME DP - Unbound Medicine ER -